BlinkLab is trading at A$0.85, up 26.87%; no new company-specific announcement explaining the August 19, 2026 move was identified.
- The latest material update remains the positive European ADHD study, reporting 82% sensitivity and 83% specificity.
- Healthcare-sector strength may provide supporting context, but the catalyst remains unconfirmed.
- Trading activity appears elevated relative to recent sessions.